Integra Lifesciences Holdings (IART) Cash from Financing Activities (2009 - 2026)

Integra Lifesciences Holdings (IART) has 18 years of Cash from Financing Activities data on file, last reported at $8.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 76.55% year-over-year to $8.3 million; the trailing twelve-month figure through Mar 2026 stood at $1.3 million (up 101.47% YoY), and the FY2025 full-year result was $28.3 million, down 88.09% from the prior year.
• Cash from Financing Activities declined to $8.3 million in Q1 2026, from $24.3 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $358.7 million in Q1 2024 to a low of -$162.7 million in Q1 2023.
• A 5-year average of -$12.2 million and a median of -$10.7 million in 2023 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities plunged 18852.21% in 2022 and jumped 440.45% in 2025, its largest moves.
• Tracing IART's Cash from Financing Activities over 5 years: stood at -$97.7 million in 2022, then jumped by 92.95% to -$6.9 million in 2023, then dropped by 3.77% to -$7.2 million in 2024, then jumped by 440.45% to $24.3 million in 2025, then sank by 65.91% to $8.3 million in 2026.
• Business Quant data shows IART's Cash from Financing Activities at $8.3 million in Q1 2026, $24.3 million in Q4 2025, and -$10.2 million in Q3 2025.